Stock Ratings / Health Care / ADVB / insiders

ACON (24) BGLC (30) AMS (29) SERA (40) ⌘ Pro Terminal →

Advanced Biomed Inc. (ADVB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are ADVB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ADVB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$2.64 -11.41% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Advanced Biomed Inc. (ADVB) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $4.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADVB)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ADVB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ADVB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ADVB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADVB)

✓Walkthrough of ADVB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADVB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.65%▼ SUPPORT BREAKDOWN

2026-10-30O $2.82H $2.82L $2.25C $2.64VOL 21.8K

RES: $12.43SUP: $6.45SMA50: $6.52SMA200: $5.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADVB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADVB Butterfly Map → + Track ADVB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADVB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADVB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADVB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADVB)

Health Care Rank #904 of 1016 ⚔️ ACON vs ADVB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADVB vs. ACON, BGLC, AMS, SERA)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Advanced Biomed Inc. (ADVB) ranks #904 by composite RQD confidence (32/100, grade E) and #955 by equity capitalization ($4.4M). Within this direct 5-issuer industry benchmark cohort, ADVB leads on earnings valuation at N/A trailing P/E, while ADVB leads on capital efficiency and profitability with -9.1% ROIC and — gross margin. SERA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ADVB at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADVB ACTIVE Advanced Biomed Inc.	E	32/100	—	—	-9.1%	-11.41%	$4.4M	Benchmark Subject
ACON Aclarion Inc.	E	24/100	—	9.0%	-35.0%	-3.43%	$5.7M	/acon-vs-advb →
BGLC BioNexus Gene Lab Corp	E	30/100	—	14.6%	-35.0%	-7.79%	$2.9M	/bglc-vs-advb →
AMS American Shared Hospital Services	E	29/100	—	18.0%	-13.8%	-5.26%	$8.4M	/ams-vs-advb →
SERA Sera Prognostics Inc. (Class A)	D-	40/100	—	-30.0%	-35.0%	+1.48%	$81.3M	/sera-vs-advb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001941029

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Advanced Biomed Inc. (ADVB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$3.3M, operating cash flow of -$5.8M, and free cash flow of -$5.9M (-166.2% YoY). On the balance sheet, ADVB closed FY2025 with $10.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$3.3M	-$5.8M	-$5.9M	$10.9M	—
FY2024 (FY)	2024-06-30	$0	-$2.8M	-$2.1M	-$2.2M	$4.5M	—

3. ADVB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Advanced Biomed Inc. (NASDAQ: ADVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.64 (-11.41% 1D, market cap $4.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ADVB ranks #904 in composite RQD confidence.

How does ADVB compare to ACON and BGLC in the Health Care sector?

Within the Health Care sector (Medical Specialities), ADVB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -9.1%. By comparison, ACON (Aclarion Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M) and BGLC (BioNexus Gene Lab Corp) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $2.9M). Among the 5-stock peer group, ADVB leads on earnings multiple (N/A) while ADVB leads on capital efficiency (-9.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADVB?

Per ADVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001941029), Advanced Biomed Inc. generated $0 in revenue, -$3.3M in net income, and -$5.9M in free cash flow against $10.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADVB trading relative to its 50-day, 200-day, and 52-week technical levels?

ADVB last traded at $2.64 (-11.41% on volume of 26,235 shares), positioning the stock -59.51% below its 50-day simple moving average ($6.52) and -55.41% below its 200-day simple moving average ($5.92). Across its 52-week range of $2.25 to $24.23, ADVB sits at the 1.8% percentile with a 14-day RSI of 20.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.31 to $2.97).

ADVB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ADVB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ADVB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ADVB RQD Cockpit ADVB 12M Forecast ADVB Earnings & Move ADVB Dividends & DRIP ADVB Insiders & 13F ADVB Whale Options ADVB Profit Sankey ADVB News & Why